D. Schoepp. There is a medical need for novel antipsychotic drugs. Currently available drugs modulate dopamine receptors and do not affect cognitive domain of the disease. There also problems with compliance and tolerability of drugs. Schoepp advocates the use of glutamate receptor modulators in the therapy of schizophrenia.